Vitamin K found in some cheeses could help fight Covid-19, study suggests
Scientists in Netherlands explore possible link between deficiency and Covid-19 deathsCoronavirus – latest updatesSee all our coronavirus coveragePatients who have died or been admitted to intensive care with Covid-19 have been found to be deficient in a vitamin found in spinach, eggs, and hard and blue cheeses, raising hopes that dietary change might be one part of the answer to combating the disease.Researchers studying patients who were admitted to the Canisius Wilhelmina hospital in the Dutch city of Nijmegen have extolled the benefits of vitamin K after discovering a link between deficiency and the worst coronavirus...
Source: Guardian Unlimited Science - June 5, 2020 Category: Science Authors: Daniel Boffey in Brussels Tags: Medical research Coronavirus outbreak Netherlands Health Europe Infectious diseases Science Healthcare industry & wellbeing Source Type: news
Vitamin K Antagonists and Osteoporotic Fractures Vitamin K Antagonists and Osteoporotic Fractures
A new study compared the fracture risks associated with NOACs vs. warfarin among AF patients on anticoagulant therapy. Which presents a better safety profile as it relates to bone health?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Safety, Effectiveness of VKAs, DOACs Similar in General Practice
THURSDAY, March 12, 2020 -- For patients receiving anticoagulants, arteriovenous events and major bleeding events do not differ for those receiving vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs), according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 12, 2020 Category: Pharmaceuticals Source Type: news
Abbott Wins Approval for CATALYST Trial for At-Risk Stroke Patients
This study is an extremely important step in assessing the Amplatzer Amulet as an effective non-prescription drug alternative for patients with AFib who are at an increased risk for ischemic stroke."
In an email sent to MD+DI, Abbott wrote, “We already have an Amulet IDE trial underway that is intended to support our submission for approval in the U.S. for Amplatzer Amulet. The newly announced CATALYST trial will support our submission for an expanded indication for Amulet as a safe and effective alternative to NOAC drugs for patients with atrial fibrillation and at risk of stroke.â€
Abbo...
Source: MDDI - February 3, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Regulatory and Compliance Source Type: news
Abbott Announces First-of-Its-Kind Trial to Assess New Therapy Option for People at Risk of Stroke
- The CATALYST trial will examine Abbott's Amplatzer ™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation (Source: Abbott.com)
Source: Abbott.com - February 3, 2020 Category: Pharmaceuticals Source Type: news
Non-vitamin K Antagonist Oral Anticoagulants Beyond AF Non-vitamin K Antagonist Oral Anticoagulants Beyond AF
Several new studies are investigating the use of NOACs in other medical conditions beyond stroke prevention in AF and the prevention or treatment of VTE.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Compared With Warfarin, Non-Vitamin K Antagonist Oral Anticoagulants May Better Limit Risks to Bone Health
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - January 25, 2020 Category: Orthopaedics Tags: Trends and Innovations Source Type: news
Older adults — particularly men — need to make sure they get enough vitamin K
Research shows that too little of the nutrient is associated with various age-related concerns, such as cognitive function, heart health and mobility. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - December 3, 2019 Category: Consumer Health News Authors: Consumer Reports Source Type: news
Audio reveals Illinois doctors planning to seize babies to give them vitamin K shots
Parents in Illinois claim that hospitals there temporarily seized their newborns after they refused a vitamin K shot and called on them to be investigated for neglect, a policy since rescinded. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2019 Category: Consumer Health News Source Type: news
Study Compares Anticoagulants for Antiphospholipid Syndrome
TUESDAY, Oct. 15, 2019 -- In thrombotic antiphospholipid antibody syndrome (APS), rivaroxaban is not noninferior to dose-adjusted vitamin K antagonists (VKAs), according to a study published online Oct. 15 in the Annals of Internal Medicine.
Josep... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 15, 2019 Category: Pharmaceuticals Source Type: news
14.10.19: Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTEmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 14, 2019 Category: Pharmaceuticals Source Type: news
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients (for specialized target groups only)
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE (Source: Bayer Company News)
Source: Bayer Company News - October 14, 2019 Category: Pharmaceuticals Source Type: news
Dying to be ill: Munchausen meets warfarin overdose - Akella P, Jindal V, Maradana S, Siddiqui AD.
Patients with severe coagulopathy related to vitamin K deficient proteins can be associated with surreptitious ingestion of vitamin K antagonists. Our patient presented acutely with extensive ecchymosis, gingival bleeding and hematuria. Her initial PT and ... (Source: SafetyLit)
Source: SafetyLit - September 28, 2019 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
ENTRUST-AF PCI Supports Safety of Dual Therapy With Edoxaban ENTRUST-AF PCI Supports Safety of Dual Therapy With Edoxaban
ENTRUST AF-PCI completes the trials of NOACs in patients with AF who undergo PCI, showing dual therapy with edoxaban was noninferior to vitamin K-antagonist – based triple therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
RE-SPECT-CVT-Study-data-published
Results from RE-SPECT CVT ® published - first trial of NOAC in cerebral venous thrombosisStudy published in JAMA Neurology investigated Pradaxa ® (dabigatran etexilate) in patients with cerebral venous and dural sinus thrombosis (CVT)First exploratory study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this populationThe study is part of Boehringer Ingelheim ’s commitment to advancing thrombosis care (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 4, 2019 Category: Research Source Type: news
